OUR PRODUCTS
Our Pipeline
We challenge ourselves to rethink the way medicines are developed,
and
are investing now to bring more value to patients in the future.
We strive for constant innovation and we are putting our passion and expertise to work in new areas including gastroenterology and endocrinology.
SB15i
Biosimilar candidate
- Molecule Aflibercept
- Reference Biologic Eyleaii
- Therapeutic Area Ophthalmology
SB16
Biosimilar candidate
- Molecule Denosumab
- Reference Biologic Proliaiii
- Therapeutic Area Endocrinology
SB17
Biosimilar candidate
- Molecule Ustekinumab
- Reference Biologic Stelaraiv
- Therapeutic Area immunology
SB26
Novel biologic
- Molecule Ulinastatin-Fc
Fusion Protein - Therapeutic Area Gastroenterology
*Pipeline last updated June 2023
- iPhase I clinical trial was waived for SB15
- iiEylea is a registered trademark of Regeneron
- iiiProlia is a registered trademark of Amgen
- ivStelara is a registered trademark of Janssen
